StockMirror — Stock Screener

JAGSNPHARM Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: medium)

Earnings Summary

Jagsonpal Pharmaceuticals reported Q2 FY27 standalone revenue growth of 9.3% YoY to INR81 cr and consolidated revenue of INR96 cr (+29% YoY). Gross margin improved ~70 bps YoY, EBITDA margin stable at 22.7% standalone despite investments. Management expressed confidence in accelerating growth to >1.5x IPM in Q3, crossing INR100 cr quarterly revenue, and achieving INR500 cr by FY28 organically. Two acquisitions (Aequitas and Group Pharma Wellness) were completed, adding hospital channel and geographical expansion. Cash balance strong at INR135 cr. Key risks include integration execution and pricing pressure in hospital segment.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasizes achieving INR500 cr revenue by FY28 while improving EBITDA margins to >22% on consolidated basis through operating leverage and mix improvement.

About Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More